Hepatitis C related liver failure and hepatocarcinoma are the most common indications for liver transplantation in Western countries. Recurrent hepatitis C infection of the allograft is universal and immediate following liver transplantation, being associated with accelerated progression to cirrhosis, graft loss and death. Graft and patient survival is reduced in liver transplant recipients with recurrent Hepatitis C virus (HCV) infection compared to HCV-negative recipients. Many variables may impact on recurrent HCV liver disease. Overall, excess immunosuppression is believed to be a key factor; however, no immunosuppressive regimen has been identified to be more beneficial or less harmful. Donor age limitations, exclusion of moderately to severely steatotic livers and minimization of ischemic times could be a potential strategy to minimize the severity of HCV disease in transplanted subjects. After transplantation, antiviral therapy based on pegylated IFN alpha with or without ribavirin is associated with far less results than that reported for immunocompetent HCV-infected patients. New findings in the field of immunotherapy and genomic medicine applied to this context are promising.

Carbone, M., Lenci, I., Baiocchi, L. (2012). Prevention of hepatitis C recurrence after liver transplantation: An update. WORLD JOURNAL OF GASTROINTESTINAL PHARMACOLOGY AND THERAPEUTICS, 3(4), 36-48 [10.4292/wjgpt.v3.i4.36].

Prevention of hepatitis C recurrence after liver transplantation: An update

CARBONE, MARCO
Primo
;
2012

Abstract

Hepatitis C related liver failure and hepatocarcinoma are the most common indications for liver transplantation in Western countries. Recurrent hepatitis C infection of the allograft is universal and immediate following liver transplantation, being associated with accelerated progression to cirrhosis, graft loss and death. Graft and patient survival is reduced in liver transplant recipients with recurrent Hepatitis C virus (HCV) infection compared to HCV-negative recipients. Many variables may impact on recurrent HCV liver disease. Overall, excess immunosuppression is believed to be a key factor; however, no immunosuppressive regimen has been identified to be more beneficial or less harmful. Donor age limitations, exclusion of moderately to severely steatotic livers and minimization of ischemic times could be a potential strategy to minimize the severity of HCV disease in transplanted subjects. After transplantation, antiviral therapy based on pegylated IFN alpha with or without ribavirin is associated with far less results than that reported for immunocompetent HCV-infected patients. New findings in the field of immunotherapy and genomic medicine applied to this context are promising.
Articolo in rivista - Articolo scientifico
Hepatitis C; Immunosuppression; Liver transplantation; Recurrence; Treatment
English
36
48
13
Carbone, M., Lenci, I., Baiocchi, L. (2012). Prevention of hepatitis C recurrence after liver transplantation: An update. WORLD JOURNAL OF GASTROINTESTINAL PHARMACOLOGY AND THERAPEUTICS, 3(4), 36-48 [10.4292/wjgpt.v3.i4.36].
Carbone, M; Lenci, I; Baiocchi, L
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/141330
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
Social impact